Amy Reilly

Investor Relations Contact at DYNE THERAPEUTICS, INC.

51 year

Health Technology

Consumer Services

Profile

Amy Reilly is currently the Head of Corporate Communication & Investor Relations at Dyne Therapeutics, Inc. She previously worked as the Director of Corporate Communications at ImmunoGen, Inc. from 2015 to 2017.
Prior to that, she was the Director of Employee Communications & Philanthropy at Cubist Pharmaceuticals LLC from 2013 to 2015.
In 2017, she briefly served as the Senior Director of Internal Communications at Thermo Fisher Scientific, Inc. From 2018 to 2020, she held the position of Vice President of Communications & Investor Relations at Kaleido Biosciences, Inc. Ms. Reilly completed her undergraduate degree at Bowdoin College.

Amy Reilly active positions

Companies	Position	Start
DYNE THERAPEUTICS, INC.	Investor Relations Contact	2020-06-30

All active positions of Amy Reilly

Former positions of Amy Reilly

Companies	Position	End
KALEIDO BIOSCIENCES, INC.	Investor Relations Contact	2020-04-30
THERMO FISHER SCIENTIFIC	Public Communications Contact	2017-09-30
IMMUNOGEN, INC.	Public Communications Contact	2017-02-28
CUBIST PHARMACEUTICALS INC	Public Communications Contact	2014-12-31

See the detail of Amy Reilly's experience

Training of Amy Reilly

Bowdoin College

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Amy Reilly's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
KALEIDO BIOSCIENCES, INC.	Health Technology
DYNE THERAPEUTICS, INC.	Health Technology
THERMO FISHER SCIENTIFIC	Health Technology

Private companies	2
Cubist Pharmaceuticals LLC Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.	Health Technology
ImmunoGen, Inc. ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.	Health Technology

See company connections